Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

The oral exposure challenge in PROTACs: What drug developers need to solve early

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at drugdiscoverytrends.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

PROTAC drugs face significant challenges in achieving effective oral exposure due to their large size and complex chemical properties, requiring drug developers to address multiple factors early in development including food effects and pharmacokinetic optimisation.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must prioritise evaluating food effects and solubility early in your PROTAC development to unlock oral dosing potential. Missing this step guarantees late-stage failures that kill your chances for clinical success.

◆ Coverage

1 source · 31 Aug 2026

◆ Related on Wire

◆ Topics

Biotechprotacsoral-exposuredrug-developmentbioavailabilitypharmacokinetics